Immune cell activity during anti-TNF treatment in patients with psoriasis and psoriatic arthritis
Clinical and Experimental Immunology · 2024
DOI: 10.1093/cei/uxae070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Aleksandra Petrovic und 10 weiteren Autor:innen. Beteiligte Einrichtung: Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Infliximab, Arthritis, Psoriatic, Killer Cells, Natural, Psoriasis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Faculty of Medicine, University of Bergen.
Abstract (Originalsprache)
Psoriasis is a chronic, inflammatory skin disease characterized by a dysregulated immune response and systemic inflammation. Up to one-third of patients with psoriasis have psoriatic arthritis (PsA). Targeted treatment with antibodies neutralizing tumor necrosis factor can ameliorate both diseases. We here explored the impact of long-term infliximab treatment on the composition and activity status of circulating immune cells involved in chronic skin and joint inflammation. Immune cells were analyzed by multicolor flow cytometry. We measured markers of immune activation in peripheral blood mononuclear cell populations in 24 infliximab-treated patients with psoriasis/PsA compared to 32 healthy controls. We observed a significant decrease in the frequency of both peripheral natural killer (NK) cells and their subset CD56dimCD16+ NK cells in PsA compared to healthy controls and patients with psoriasis. The latter had a strong-positive correlation with psoriasis area severity index (PASI) in these patients, while CD56brightCD16− NK cells were negatively correlated with PASI. In addition, we observed an upregulation of CD69+ intermediate CD14+CD16+ and CD69+ classical CD14+CD16− monocytes in PsA and increased activity of CD38+ intermediate CD14+CD16+ monocytes in patients with psoriasis. Compared to healthy controls, psoriasis patients demonstrated shifts of the three B-cell subsets with a decrease in transitional CD27-CD38high B cells. Our exploratory study indicates a preserved pathophysiological process including continuous systemic inflammation despite clinical stability of the patients treated with infliximab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
- Flow Cytometry Core Facility, Department of Clinical Science, University of Bergen, Bergen, Norway.
- Department of Dermatology, Haukeland University Hospital, Bergen, Norway.
- Department of Clinical Medicine, University of Bergen, Bergen, Norway.
ORCID-Profile: Silke Appel
Förderung
- Faculty of Medicine, University of Bergen
Zitieren
APA
Petrovic, A., Samuelsen, V. M., Davies, R., Aarebrot, A. K., Holmes, T., Sarkar, I., Bergum, B., Jonsson, R., Sandvik, L. F., Solberg, S. M., & Appel, S. (2024). Immune cell activity during anti-TNF treatment in patients with psoriasis and psoriatic arthritis. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae070
Vancouver
Petrovic A, Samuelsen VM, Davies R, Aarebrot AK, Holmes T, Sarkar I, et al. Immune cell activity during anti-TNF treatment in patients with psoriasis and psoriatic arthritis. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxae070
BibTeX
@article{Petrovic2024,
author = {Petrovic, Aleksandra and Samuelsen, Victoria Marie and Davies, Richard and Aarebrot, Anders K and Holmes, Timothy and Sarkar, Irene and Bergum, Brith and Jonsson, Roland and Sandvik, Lene F and Solberg, Silje M and Appel, Silke},
title = {Immune cell activity during anti-TNF treatment in patients with psoriasis and psoriatic arthritis},
journal = {Clinical and Experimental Immunology},
year = {2024},
doi = {10.1093/cei/uxae070}
}
EUVIMED